8-K: STAAR Surgical Reports Strong Q1 Growth and Reaffirms Positive Outlook for EVO ICL

STAAR Surgical's investor presentation highlights strong first-quarter growth, increased market share for its EVO ICL product, and a positive outlook for future expansion.

Summary

• STAAR Surgical presented to investors on June 12, 2024, detailing their first-quarter performance and future growth plans.
• The company reported a 9% global ICL sales growth in Q1 2024, with regional growth of 12% in the Americas, 11% in EMEA, and 9% in APAC.
• U.S. ICL sales saw a 21% sequential growth, reaching a record $5 million for the quarter.
• STAAR has sold over 3 million ICLs, with more than 1.5 million sold in the last three years (2021-2023).
• The company is targeting $335 to $340 million in net sales for fiscal year 2024, with an adjusted EBITDA of approximately $39 million and adjusted EBITDA per diluted share of around $0.75.
• STAAR anticipates selling more ICLs in the next three years (2024-2026) than in the first 25 years of ICL sales combined.
• The company is expanding into new markets, including the U.S., Mexico, Indonesia, Brazil, and India, and is focusing on the growing middle class in these regions.
• STAAR is also investing in new product innovations, such as Presbyopia, EVO VIVA, and next-generation EVO products.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong growth metrics, market share gains, and a clear strategic vision. While there are some macroeconomic headwinds, the overall tone is optimistic and confident.

Positives

• STAAR is experiencing strong sales growth across all regions.
• The company's EVO ICL product is gaining significant market share.
• There is a high level of surgeon confidence in the EVO ICL product.
• STAAR is expanding into new and emerging markets.
• The company has a strong cash position with $252.1 million in cash, cash equivalents, and investments available for sale as of March 29, 2024.
• STAAR is making strategic investments in people and processes that are yielding positive results.
• The company is seeing a quickening pace of momentum to start 2024.
• The company has a strong focus on commercial activities.
• STAAR has a clear vision for growth through 2026.

Negatives

• The refractive industry procedure growth is down year-to-date in the first half of 2024.
• The company faces difficult comparisons due to a post-COVID-19 surge in 1H23.
• Macroeconomic headwinds are impacting the business.
• The company is experiencing flat growth in some APAC countries outside of China.

Risks

• Global economic conditions could impact sales and growth.
• The company is dependent on demand from Asia.
• Regulatory agencies could delay or reject product approvals.
• International conflicts and trade disputes could affect the business.
• The willingness of surgeons and patients to adopt new products and procedures is a risk.
• Macroeconomic headwinds could impact the business.

Future Outlook

STAAR anticipates continued growth in ICL sales, driven by market adoption and share gains. The company expects to sell more ICLs in the next three years than in the first 25 years combined. They are also targeting $500 to $550 million in sales and $60 to $90 million in operating income by fiscal year 2026.

Management Comments

• Our first quarter results illustrate the impact of our commercial focus, which is driving continued market adoption and share gains of our EVO ICL.
• Our strategic investments in people and processes in recent quarters are now bearing fruit.
• We are very pleased by the quickening pace of our momentum to start 2024, marked by several significant business milestones, including todays announcement of the largest-ever practice commitment to EVO ICL in the U.S.

Industry Context

The presentation highlights STAAR's efforts to capture market share in the refractive surgery market, which is currently experiencing some headwinds. The company is positioning its EVO ICL product as a superior alternative to other vision correction procedures, emphasizing its safety, effectiveness, and patient satisfaction. The company is also expanding into new and emerging markets to capitalize on the growing middle class in these regions.

Comparison to Industry Standards

• STAAR's ICL unit growth outperformed the global refractive industry procedure growth by 26 points in 2023 and 28 points in 2022, indicating a strong competitive position.
• The company's market share capture in Japan, China, and South Korea is used as a benchmark for its potential in other markets.
• The document references Market Scope, Refractive Surgery Council, and survey data to support its market share estimates.
• The company is actively working to overcome obstacles to gain market share, similar to other medical device companies.

Stakeholder Impact

• Shareholders are likely to be positively impacted by the strong growth and positive outlook.
• Employees may benefit from the company's growth and success.
• Customers (patients) will have access to a potentially superior vision correction option.
• Surgeons will have access to a product that is gaining market share and has high levels of patient satisfaction.

Next Steps

• STAAR will continue to focus on commercial activities to drive market adoption and share gains.
• The company will continue to invest in new and emerging markets.
• STAAR will continue to develop new product innovations.
• The company will continue to engage with surgeons and healthcare professionals at industry meetings.

Key Dates

Keywords

EVO ICL, refractive surgery, myopia, vision correction, implantable collamer lens, ophthalmology, market share, sales growth, adjusted EBITDA, APAC, EMEA, Americas